Latest filing published 27 Feb 2026 for Caribou Biosciences, Inc., €10k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Timothy P. Kelly: trading record in brief
Timothy P. Kelly, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Q32 Bio Inc. and Caribou Biosciences, Inc. We count 24 filings; the first trade dates from 3 June 2019 and the latest from 25 February 2026.
Every open-market trade on record is a sale: 13 sales worth €284k. Other entries cover 2 share grants and 9 option exercises. So far in 2026, the count stands at no purchases and 2 sales.
Most recently, on 27 February 2026, the filings show an open-market sale worth €10k in Caribou Biosciences, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Timothy P. Kelly
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,228 shares@ US$1.93100.0% of flowCommon StockSEC:0001754067-26-000004:0
- 45,000 shares0Common StockSEC:0001754067-26-000002:0
- 37,500 shares0Common StockSEC:0001754067-25-000003:0
- 3,630 sharesCommon StockSEC:0000899243-22-001747:0
- 54 shares@ US$7.700.6% of flowCommon StockSEC:0000899243-21-035330:0
- 6,232 shares@ US$11.162299.4% of flowCommon StockSEC:0000899243-21-035329:0
6 of 6 declarations
